CIK 0001720893 · Non-accelerated filer<br>Smaller reporting company
BioXcel Therapeutics, Inc.
Sign in to watch- Ticker
- BTAIQ
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821386754
- Phone
- 203-643-8060
- Business address
- 555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 33 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-14 | Steinhart Richard I Chief Financial Officer | Option exercise | +31 | 1,339 | ||
| 2025-03-14 | Steinhart Richard I Chief Financial Officer | Option exercise · Restricted Stock Units | −31 | 229 | ||
| 2025-03-14 | Rodriguez Javier See Remarks | Option exercise | +31 | 1,557 | ||
| 2025-03-14 | Rodriguez Javier See Remarks | Option exercise · Restricted Stock Units | −31 | 229 | ||
| 2025-03-14 | Yocca Frank Chief Scientific Officer | Option exercise | +31 | 1,839 | ||
| 2025-03-14 | Yocca Frank Chief Scientific Officer | Option exercise · Restricted Stock Units | −31 | 229 | ||
| 2025-03-14 | Mehta Vimal CEO and President | Option exercise | +162 | 3,887 | ||
| 2025-03-14 | Mehta Vimal CEO and President | Option exercise · Restricted Stock Units | −162 | 1,142 | ||
| 2025-02-28 | MACK DAVID J. Director | Option exercise | +1,693 | 6,772 | ||
| 2025-02-28 | MACK DAVID J. Director | Option exercise · Restricted Stock Units | −1,693 | 13,545 | ||
| 2025-01-31 | MACK DAVID J. Director | Option exercise | +27,089 | 81,267 | ||
| 2025-01-31 | MACK DAVID J. Director | Option exercise · Restricted Stock Units | −27,089 | 243,810 | ||
| 2025-01-15 | Patni Rajiv Director | Grant or award · Stock Option (right to buy) | +44,000 | 44,000 | ||
| 2025-01-07 | Mehta Vimal CEO and President | Grant or award · Stock Option (right to buy) | +660,000 | 660,000 | ||
| 2025-01-07 | Yocca Frank Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +270,000 | 270,000 | ||
| 2025-01-07 | Steinhart Richard I Chief Financial Officer | Grant or award · Stock Option (right to buy) | +270,000 | 270,000 | ||
| 2024-12-31 | MACK DAVID J. Director | Option exercise 10b5-1 | +27,089 | 54,178 | ||
| 2024-12-31 | MACK DAVID J. Director | Option exercise · Restricted Stock Units 10b5-1 | +27,089 | 270,899 | ||
| 2024-12-16 | O'Neill Vincent See Remarks | Sale 10b5-1 | −165 | $0.35 | $58 | 19,957 |
| 2024-12-16 | Mehta Vimal CEO and President | Sale 10b5-1 | −983 | $0.36 | $358 | 60,920 |
Page 8 of 27 · 521 trades